(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases ...
(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases ...